Joint Comments Regarding NIH Proposed Exclusive License to Intima Biosciences for Cancer Therapy

On September 13, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen (PC), Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love submitted comments regarding the “Prospective Grant of an Exclusive Patent… Continue Reading

KEI Request Re: Failure to Disclose Federal Funding in UPenn Bennett et al Patents for Gene Therapy to Treat Blindness

On September 9, 2019, KEI submitted a second request to the NIH that it investigate an apparent failure to disclose federal funding in patents in adeno-associated viral (AAV) gene therapies assigned to the Trustees of the University of Pennsylvania (UPenn).… Continue Reading

Zolgensma

Zolgensma is a gene therapy for spinal muscular atrophy (SMA) that was approved by the US FDA in May 2019, at a price of $2.1 million per patient. Zolgensma was licensed from a children’s hospital where it was developed on… Continue Reading

KEI Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead

On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI, Social Security Works (SSW), Universities Allied for Essential Medicines (UAEM), Union for Affordable Cancer Treatment (UACT), and Clare Love, a cancer… Continue Reading

KEI Letter to US House Oversight Committee on NIH Misconduct and Lack of Transparency

On July 22, 2019, Knowledge Ecology International submitted a letter to the US House of Representative’s Committee on Oversight and Reform regarding the National Institutes of Health’s (NIH) lack of transparency in its exclusive licensing processes. Prior to executing an… Continue Reading